Financial Costs, Benefits, and Patient Risk Preferences in Node-Negative Breast Cancer: Insights from a Decision Analysis Model
- 1 January 1993
- book chapter
- Published by Springer Nature
- Vol. 127, 277-284
- https://doi.org/10.1007/978-3-642-84745-5_36
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapyThe Lancet, 1992
- Cost Effectiveness of Prophylactic Intravenous Immune Globulin in Chronic Lymphocytic LeukemiaNew England Journal of Medicine, 1991
- Efficacy and Cost Effectiveness of Adjuvant Chemotherapy in Women with Node-Negative Breast CancerNew England Journal of Medicine, 1991
- Treatment of Early-Stage Breast CancerJAMA, 1991
- Estimating the Treatment Costs of Breast and Lung CancerMedical Care, 1991
- Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public.BMJ, 1990
- Cost Effectiveness of Bone Marrow Transplantation in Acute Nonlymphocytic LeukemiaNew England Journal of Medicine, 1989
- Decision AnalysisNew England Journal of Medicine, 1987
- Cost-effectiveness Analysis of End-stage Renal Disease TreatmentsMedical Care, 1987